Kahr has developed a technology platform based on bi-functional, immunotherapeutic fusion proteins known as Dual Signalling Proteins (DSP). The technology is based on scientific work of Prof. Michal Elhalel Dranitzki from Hadasah Ein Karem and Dr. Mark L. Tykocinski from Jefferson Pennsylvania University. The technology enables Kahr to develop proteins that, in contrast to normal therapies, address more than one active element in a cancer cell. This technology allows to target the cancerous cell and not affect normal cells, contributing to the drugs safety, and once targeted, to engage the immune system in order to attack the tumour.